Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Boston IVF and IviGen partner to improve fertility outcomes

Boston IVF, a provider of in vitro fertilization services in the US, IviGen and its parent company iGenomix, worldwide providers of advanced services in reproductive genetics, have announced a partnership which will provide comprehensive genetic testing services to Boston IVF patients.

Boston IVF medical director and president Dr. Michael Alper said: "We’re very pleased to be partnering with IviGen, a leader in the field of genetic testing, to provide the most advanced and productive testing services to our couples undergoing reproductive health counseling and treatments.

"This partnership will allow Boston IVF to offer the most advanced genetic screening technologies for IVF patients and their embryos, and at a price point that makes these technologies more readily available."

The relationship brings together Boston IVF’s premier reproductive health services with IviGen’s advanced, genetics-based reproductive health products, including:

Preimplantation genetic screening (PGS), a test performed in conjunction with IVF to screen embryos for chromosomal abnormalities. Studies suggest PGS can improve IVF pregnancy rates by helping clinicians identify the most viable embryos prior to transfer.

Preimplantation genetic diagnosis (PGD), a test performed in conjunction with IVF treatment to identify single gene disorders among embryos produced by couples who are at risk of having a child with a particular genetic disease. PGD can help reduce the risk of a particular disorder being passed onto a child.

Products of conception (POC) testing, which evaluates tissue from a pregnancy loss for chromosome abnormalities in order to help determine cause of the miscarriage. POC testing can help patients and caregivers evaluate future reproductive care options.

Endometrial receptivity array (ERA®). ERA evaluates the expression of a group of genes related to endometrial receptivity to determine the optimal timing for embryo transfer and implantation. Early studies suggest that ERA may improve reproductive success for some couples, by identifying the optimal, personalized time for embryo transfer.

Sperm aneupoloidy test (SAT), a genetic test that determines whether there is an increased incidence of significant chromosome abnormalities in sperm. SAT can help some patients and caregivers evaluate future reproductive care options.

IviGen and iGenomix CEO David Jimenez said: "IviGen’s mission is to become the leading provider of genetic testing services to the reproductive health community and this agreement represents a great opportunity for us to work with one of the most advanced teams in the world in genetic testing and reproductive health.

"This partnership also allows us to collaborate in the research and development of new tools to prevent infertility and improve treatment outcomes."